Search
Cyclophosphamide Treatment Options
A collection of 2150 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
1837 - 1848 of 2150
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill cancer cells. It is not yet known which regimen of chemotherapy combined with vaccine therapy is more effective for non-Hodgkin's lymphoma.
PURPOSE: Randomized phase III trial to determine the effectiveness of combination chemotherapy followed by vaccine therapy plus sargramostim in treating patients who have stage I... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2013
Locations: SuperGen, Incorporated, Dublin, California +23 locations
Conditions: Lymphoma
Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. GM-CSF may make cancer cells more sensitive to the effects of chemotherapy. Combining more than one drug with GM-CSF may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, consisting of cyclophosphamide plus vincristine, following GM-CSF in treating patients with multiple myeloma that has not responded to previous treatment.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
12/03/2013
Locations: Cleveland Clinic Cancer Center, Cleveland, Ohio
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
Completed
Cyclophosphamide is a chemotherapy agent with known activity in myeloma. The new regimen that we will test in this study is called CVDD and contains Cyclophosphamide with Bortezomib (VELCADE), Pegylated Liposomal Doxorubicin (DOXIL®, PLD), and Dexamethasone (VDD).
The purpose of this study is to determine if the addition of another type of chemotherapy agent, Cyclophosphamide, to the regimen VDD (CVDD) is well tolerated and improves response rates in myeloma. We will also find the highest safe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2013
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Multiple Myeloma
Biological Therapy in Treating Patients With Glioblastoma Multiforme
Completed
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating patients with glioblastoma multiforme.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2013
Locations: Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio
Conditions: Brain and Central Nervous System Tumors
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
Completed
The purpose of this research study is to study the effects (good and bad) of bevacizumab alone, bevacizumab with low-dose continuous chemotherapy (called metronomic chemotherapy), or bevacizumab with capecitabine, on you and your cancer. The goals of the study will be to:
* Examine the safety of these drugs
* See how easy or difficult it is to be treated with them
* Monitor for any signs of recurrent cancer
* Look at blood markers that might indicate how the treatment is working
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2013
Locations: University of California, San Francisco, San Francisco, California +4 locations
Conditions: Breast Cancer
High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment
Terminated
The purpose of this study is to evaluate the toxicity and the effectiveness of high dose chemotherapy with HPC transplant Multiple Sclerosis that has failed at least two lines of therapy
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
11/21/2013
Locations: Amarillo Diagnostic Clinic, Amarillo, Texas +2 locations
Conditions: Multiple Sclerosis
ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer
Completed
The purpose of this research study is to determine the safety and tolerability of the combination of Zactima with metronomic chemotherapy. Zactima is an oral anti-angiogenesis drug, which means it fights cancer by cutting off a tumor's blood supply. Thus, the drug starves the tumor by preventing the delivery of nutrients and oxygen. Metronomic chemotherapy is low dose oral chemotherapy pills which are taken daily. Unlike traditional chemotherapy, metronomic chemotherapy is thought to fight cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2013
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Metastatic Breast Cancer
Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Unknown
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an im... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/05/2013
Locations: Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California
Conditions: Graft Versus Host Disease, Leukemia
Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
Unknown
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody and cyclophosphamide in treating patients with metastatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2013
Locations: St. Vincent Medical Center - Los Angeles, Los Angeles, California
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer
Completed
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and cyclophosphamide, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
10/28/2013
Locations: Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Terminated
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving a monoclonal antibody, such as alemtuzumab,... Read More
Gender:
ALL
Ages:
Between 40 years and 72 years
Trial Updated:
10/28/2013
Locations: Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Completed
RATIONALE: Giving two autologous stem cell transplants (one after the other) may be an effective treatment for Hodgkin's lymphoma.
PURPOSE: This phase II trial is studying how well giving two autologous stem cell transplants works in treating patients with progressive or recurrent Hodgkin's lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2013
Locations: Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Lymphoma
1837 - 1848 of 2150